{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:36:03Z","timestamp":1761237363430,"version":"3.44.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.expneurol.2006.08.026","type":"journal-article","created":{"date-parts":[[2006,10,15]],"date-time":"2006-10-15T06:45:08Z","timestamp":1160894708000},"page":"415-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease"],"prefix":"10.1016","volume":"203","author":[{"given":"Dieter","family":"Scheller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piu","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Ravenscroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine","family":"Guigoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2006.08.026_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ar.1090940210","article-title":"Estimation of nuclear population from microtome sections","volume":"94","author":"Abercrombie","year":"1946","journal-title":"Anat. Rec."},{"key":"10.1016\/j.expneurol.2006.08.026_bib2","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1073\/pnas.0400569101","article-title":"Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease","volume":"101","author":"Benner","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2006.08.026_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0006-8993(97)00531-3","article-title":"A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey","volume":"766","author":"Bezard","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2006.08.026_bib4","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","article-title":"Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease","volume":"21","author":"Bezard","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2006.08.026_bib5","doi-asserted-by":"crossref","first-page":"10999","DOI":"10.1523\/JNEUROSCI.23-35-10999.2003","article-title":"Enriched environment confers resistance to MPTP and cocaine: involvement of dopamine transporter and neurotrophic factors","volume":"23","author":"Bezard","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2006.08.026_bib6","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm875","article-title":"Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function","volume":"9","author":"Bezard","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.expneurol.2006.08.026_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nbd.2006.02.003","article-title":"5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease","volume":"23","author":"Bezard","year":"2006","journal-title":"Neurobiol. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2006.08.026_bib8","first-page":"40","article-title":"Quantitative assessment of dyskinesias in subhuman primates","volume":"14","author":"Brotchie","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2006.08.026_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0014-2999(97)00037-X","article-title":"Regulation of tyrosine hydroxylase and aromatic l-amino acid decarboxylase by dopaminergic drugs","volume":"323","author":"Cho","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2006.08.026_bib10","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/sj.gt.3301033","article-title":"Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat","volume":"6","author":"Connor","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.expneurol.2006.08.026_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1006\/exnr.2001.7638","article-title":"Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration","volume":"169","author":"Connor","year":"2001","journal-title":"Exp. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2006.08.026_bib12","first-page":"73","article-title":"Temporospatial progression of the loss of dopaminergic neurons in the substantia nigra in Parkinson's disease","volume":"12","author":"Damier","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2006.08.026_bib13","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/brain\/122.8.1421","article-title":"The substantia nigra of the human brain\u2014I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D-28K immunohistochemistry","volume":"122","author":"Damier","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2006.08.026_bib14","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","article-title":"The substantia nigra of the human brain\u2014II. Patterns of loss of dopamine-containing neurons in Parkinson's disease","volume":"122","author":"Damier","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2006.08.026_bib15","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/nn941","article-title":"Neuroprotective and neurorestorative strategies for Parkinson's disease","author":"Dawson","year":"2002","journal-title":"Nat. Neurosci."},{"issue":"Suppl. 4","key":"10.1016\/j.expneurol.2006.08.026_bib16","first-page":"IV37","article-title":"Does levodopa slow or hasten the rate of progression of Parkinson's disease?","volume":"252","author":"Fahn","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.expneurol.2006.08.026_bib17","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2006.08.026_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1602\/neurorx.1.1.139","article-title":"Neurodegeneration and neuroprotection in Parkinson disease","volume":"1","author":"Fahn","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.expneurol.2006.08.026_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0361-9230(96)00161-X","article-title":"A stereotaxic atlas of the basal ganglia in macaques","volume":"41","author":"Fran\u00e7ois","year":"1996","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.expneurol.2006.08.026_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1460-9568.2005.04196.x","article-title":"Levodopa-induced dyskinesia in MPTP-treated macaque is not dependent of the extent and pattern of the nigrostrial lesion","volume":"22","author":"Guigoni","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2006.08.026_bib21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.104.066191","article-title":"Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"310","author":"Hill","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2006.08.026_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-0270(99)00184-3","article-title":"Comparison between eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the macaque monkey","volume":"96","author":"Imbert","year":"2000","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.expneurol.2006.08.026_bib23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/mds.870120502","article-title":"The dopamine transporter: a crucial component regulating dopamine transmission","volume":"12","author":"Jaber","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2006.08.026_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/1055-8330(95)90015-2","article-title":"Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"4","author":"Jackson-Lewis","year":"1995","journal-title":"Neurodegeneration"},{"key":"10.1016\/j.expneurol.2006.08.026_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0163-7258(01)00139-5","article-title":"Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs","volume":"90","author":"Joyce","year":"2001","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.expneurol.2006.08.026_bib26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/mds.870120609","article-title":"Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease","volume":"12","author":"Joyce","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2006.08.026_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1741-7007-2-22","article-title":"Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor","volume":"2","author":"Joyce","year":"2004","journal-title":"BMC Biol."},{"key":"10.1016\/j.expneurol.2006.08.026_bib28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0006-8993(96)00917-1","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level","volume":"741","author":"Kupsch","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2006.08.026_bib29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002512-200118060-00001","article-title":"Are dopamine receptor agonists neuroprotective in Parkinson's disease?","volume":"18","author":"Le","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.expneurol.2006.08.026_bib30","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","article-title":"Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression","volume":"287","author":"Marek","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.expneurol.2006.08.026_bib31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tips.2004.03.003","article-title":"Neuroprotective strategies for Parkinson's disease: conceptual limits of clinical trials and animal models","volume":"25","author":"Meissner","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.expneurol.2006.08.026_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1385\/MN:28:3:209","article-title":"Time course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease","volume":"28","author":"Meissner","year":"2003","journal-title":"Mol. Neurobiol."},{"year":"1981","series-title":"Simultaneous Statistical Inference","author":"Miller","key":"10.1016\/j.expneurol.2006.08.026_bib33"},{"key":"10.1016\/j.expneurol.2006.08.026_bib34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/mds.10448","article-title":"REAL and CALM: what have we learned?","volume":"18","author":"Morrish","year":"2003","journal-title":"Mov. Disord."},{"year":"2004","series-title":"Evaluation of the Neuroprotective Effects of Rotigotine in the Progressive MPTP-Lesioned Macaque Model of Parkinson's Disease (Dose Finding)","author":"MSCCH1","key":"10.1016\/j.expneurol.2006.08.026_bib35"},{"key":"10.1016\/j.expneurol.2006.08.026_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1042\/bj20030017","article-title":"Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines","volume":"373","author":"Nair","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.expneurol.2006.08.026_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev.med.55.091902.104422","article-title":"The scientific basis for the current treatment of Parkinson's disease","volume":"55","author":"Olanow","year":"2004","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.expneurol.2006.08.026_bib38","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic l-dopa administration induces dyskinesias in the MPTP-treated common marmoset (Callithrix jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2006.08.026_bib39","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1053-8119(03)00163-0","article-title":"Presymptomatic diagnosis of experimental parkinsonism with 123I-PE2I SPECT","volume":"19","author":"Prunier","year":"2003","journal-title":"NeuroImage"},{"key":"10.1016\/j.expneurol.2006.08.026_bib40","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/01.WNL.0000149403.14458.7F","article-title":"The role of radiotracer imaging in Parkinson disease","volume":"64","author":"Ravina","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2006.08.026_bib41","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1212\/WNL.58.suppl_1.S9","article-title":"Neuroprotection and dopamine agonists","volume":"58","author":"Schapira","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2006.08.026_bib42","first-page":"S75","article-title":"Extended receptor profile of rotigotine, a non-ergolinic dopamine agonist being investigated in Parkinson's disease","volume":"21","author":"Scheller","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2006.08.026_bib43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0026-895X(25)10283-6","article-title":"Dopamine autoreceptor regulation of the kinetic state of striatal tyrosine hydroxylase","volume":"29","author":"Strait","year":"1986","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.expneurol.2006.08.026_bib44","series-title":"Toxin-Induced Models of Neurological Disorders","first-page":"139","article-title":"Behavioral effects of MPTP administration in the vervet monkey, a primate model of Parkinson's disease","author":"Taylor","year":"1994"},{"key":"10.1016\/j.expneurol.2006.08.026_bib45","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1073\/pnas.051633998","article-title":"Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"98","author":"Vila","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2006.08.026_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","article-title":"Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study","volume":"54","author":"Whone","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2006.08.026_bib47","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1523\/JNEUROSCI.22-05-01763.2002","article-title":"Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease","volume":"22","author":"Wu","year":"2002","journal-title":"J. Neurosci."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488606005279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488606005279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:34:22Z","timestamp":1758000862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488606005279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0014488606005279"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2006.08.026","relation":{},"ISSN":["0014-4886"],"issn-type":[{"type":"print","value":"0014-4886"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2006.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}